RxDoctor Payments DataLook up a doctor →

Richard Haddad, MD

Rheumatology · Red Bank, NJNPI 1750382800

Payments from drug & device makers

$1,107,786in general payments, 2019–2025

Across 3,690 payments — averaging $300.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$230K
  • Amgen$210K
  • Johnson & Johnson$149K
  • GSK$93K
  • Bristol Myers Squibb$89K
  • Lilly USA, LLC$78K
  • plus $260K from 54 others

What the payments were for

  • Consulting fees$47,2064%
  • Speaking & faculty fees$918,02383%
  • Travel & lodging$77,8117%
  • Food & beverage$63,8636%
  • Education$8840%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie565$229,531
Amgen(2 entities)646$209,611
Johnson & Johnson(2 entities)490$149,347
GSK160$92,661
Bristol Myers Squibb93$88,722
Lilly USA, LLC141$78,246
AstraZeneca(2 entities)152$44,266
Janssen Scientific Affairs, LLC28$37,231
Novartis179$35,604
Pfizer294$26,884
Sanofi69$25,749
Mallinckrodt Enterprises LLC23$20,835
UCB, Inc.85$19,046
Mallinckrodt Hospital Products Inc.67$11,398
E.r. Squibb & Sons, L.L.C.128$8,879
Medexus Pharma, Inc.21$8,791
Genentech USA, Inc.105$7,980
Regeneron Healthcare Solutions, Inc.7$3,057
Sobi, Inc16$2,819
Collegium Pharmaceutical, Inc.58$688
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC49$629
Intra-sana Laboratories9$617
Phathom Pharmaceuticals, Inc.20$457
Aurinia Pharma U.S., Inc.24$456
Boehringer Ingelheim16$445
Pacira Pharmaceuticals Incorporated16$345
Hikma Pharmaceuticals USA26$315
ANI Pharmaceuticals, Inc.15$270
Organon11$226
Idorsia Pharmaceuticals US Inc13$199
Bioventus LLC3$192
Sanofi-aventis U.S. LLC2$184
Pacira Therapeutics, Inc.29$171
Kowa Pharmaceuticals America, Inc.14$170
MDD US Operations, LLC18$168
Daiichi Sankyo Inc.13$143
Madrigal Pharmaceuticals1$133
Sandoz7$125
Zyla Life Sciences, Inc.15$119
Fresenius Kabi USA, LLC6$110
Smith+Nephew1$94
Takeda Pharmaceuticals U.S.A., Inc.7$91
Genentech, Inc.2$80
Bayer4$70
Cumberland Pharmaceuticals, Inc.3$67
Vertex3$49
Scilex Pharmaceuticals Inc.3$49
Celltrion USA Inc.3$43
Sebela Pharmaceuticals Inc.3$41
Eisai Inc.3$38
Nevro Corp.2$38
Tonix Medicines, Inc.2$38
Kiniksa Pharmaceuticals, Ltd.2$29
Tersera Therapeutics LLC2$25
USWM, LLC2$24
Radius Health, Inc.2$24
Ferring Pharmaceuticals Inc.2$24
Si-bone, Inc.1$23
United Therapeutics Corporation1$18
Forte Bio-pharma LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,107,786 in reported general payments places this provider in the 95th percentile of 234 rheumatology providers in New Jersey.

See all rheumatology providers in New Jersey

Medicare billing

Part B allowed, 2024
$6,869,696
Medicare patients
898
Services billed
520,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Simponi AriaGolimumab216$1,469,428
Enbrel SureclickEtanercept70$596,531
Cimzia (2 Pack)Certolizumab Pegol71$444,372
Xeljanz XrTofacitinib Citrate44$327,803
OtezlaApremilast65$311,794
Taltz AutoinjectorIxekizumab38$268,607
RinvoqUpadacitinib29$191,347
RayosPrednisone30$183,869
RemicadeInfliximab20$108,927
Humira(Cf)Adalimumab13$104,447
OrenciaAbatacept/Maltose20$97,055
HumiraAdalimumab12$80,048
Humira PenAdalimumab11$76,677
KevzaraSarilumab18$75,920
BenlystaBelimumab13$73,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSimponi Aria, Remicade$149,347$1,578,355236 claims
AmgenOtezla, Rayos, Prolia, Evenity (2 Syringes)$209,611$560,526128 claims
UCB, Inc.Cimzia (2 Pack)$19,046$444,37271 claims
AbbVieRinvoq, Humira(Cf), Humira, Savella$229,531$389,24466 claims
E.r. Squibb & Sons, L.L.C.Orencia$8,879$97,05520 claims
SanofiKevzara$25,749$75,92018 claims
GSKBenlysta$92,661$73,06313 claims
Scilex Pharmaceuticals Inc.Colchicine$49$7,579132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 234 rheumatology providers in New Jersey.

Other rheumatology in Red Bank

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →